Albine Martin

Dr. Albine Martin brings over 20 years of product commercialization and corporate development experience with 3 public companies located in Maryland and representing the biotechnology, diagnostics and life sciences sector. She has also served as a member of Active Angels, Inc where she syndicated and provides diligence for early stage investments. She is a member of the NSF commercial reviewer panels for SBIR 1/2 funding programs. She currently serves as COO, Precision Biologics, a clinical development oncology company with a companion diagnostic program. Precision is a clinical stage oncology company and is advancing its first program for colorectal and pancreatic cancer following the acquisition of assets from Neogenix Oncology where Dr Martin served as COO. As Vice President at Compugen (CGEN), she built the first revenue generating model and alliance management programs to advance both diagnostic and large molecule candidates. During her tenure at Life Technologies [Life] she was responsible for the global portfolio as Senior Business Director and managed Joint Ventures and expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products within the Cellular Therapy arena. She was also part of the team that led the BLA approval and commercialization of the HPV molecular diagnostic test. Dr Martin served as member of the start up team at Digene Diagnostics and led the creation of the first revenue generating business. Dr. Martin holds a PhD from the University of Maryland and served as a Staff Fellow at the National Institutes of Health and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.